- Home
- IONR vs ITOS Comparison
IONR vs ITOS Comparison
Compare IONR & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONR
- ITOS
- Stock Information
- Founded
- IONR 2001
- ITOS 2011
- Country
- IONR Australia
- ITOS United States
- Employees
- IONR N/A
- ITOS N/A
- Industry
- IONR
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IONR
- ITOS Health Care
- Exchange
- IONR Nasdaq
- ITOS Nasdaq
- Market Cap
- IONR 262.0M
- ITOS 270.7M
- IPO Year
- IONR N/A
- ITOS 2020
- Fundamental
- Price
- IONR $3.73
- ITOS $7.15
- Analyst Decision
- IONR
- ITOS Strong Buy
- Analyst Count
- IONR 0
- ITOS 3
- Target Price
- IONR N/A
- ITOS $26.00
- AVG Volume (30 Days)
- IONR 14.9K
- ITOS 410.1K
- Earning Date
- IONR 01-01-0001
- ITOS 05-09-2025
- Dividend Yield
- IONR N/A
- ITOS N/A
- EPS Growth
- IONR N/A
- ITOS N/A
- EPS
- IONR N/A
- ITOS N/A
- Revenue
- IONR N/A
- ITOS $35,000,000.00
- Revenue This Year
- IONR N/A
- ITOS N/A
- Revenue Next Year
- IONR N/A
- ITOS $31.74
- P/E Ratio
- IONR N/A
- ITOS N/A
- Revenue Growth
- IONR N/A
- ITOS 177.89
- 52 Week Low
- IONR $3.02
- ITOS $4.80
- 52 Week High
- IONR $9.35
- ITOS $18.75
- Technical
- Relative Strength Index (RSI)
- IONR 52.65
- ITOS 60.28
- Support Level
- IONR $3.73
- ITOS $4.80
- Resistance Level
- IONR $4.08
- ITOS $5.55
- Average True Range (ATR)
- IONR 0.33
- ITOS 0.43
- MACD
- IONR 0.05
- ITOS 0.20
- Stochastic Oscillator
- IONR 81.06
- ITOS 97.62
About IONR ioneer Ltd
Ioneer Ltd is a mineral exploration company. The company's focus is on the Rhyolite Ridge Lithium-Boron Project located in Nevada, USA. Geographically, the group has a business presence in Australia and North America. The company's focus is to develop a U.S.-based source of lithium and boron that can be extracted in an environmentally and socially responsible manner, providing two materials that are essential to achieve a sustainable future for the planet.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.